Clinical Trial, COVID-19, Malignant Lymphoma
Conditions
Brief summary
This study focuses on the population of malignant lymphoma patients who are also in clinical research. Through a real world cross-sectional survey of infection and death risk during the COVID-19 pandemic in Guangzhou from December 2022 to January 2023, this study aims to clarify the risk, level and mortality of lymphoma patients infected with COVID-19 during their clinical research, and provide necessary research data for Chinese lymphoma patients during the COVID-19 pandemic,
Interventions
OTHERNo intervention
No intervention needed
Sponsors
Sun Yat-sen University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
(1) the diagnosis of lymphoma was confirmed by pathology according to World Health Organization (WHO)-criteria; (2) diagnosed with COVID-19 based on a positive polymerase chain reaction (PCR) test result for SARS-CoV-2 from oropharyngeal swabs, or on a positive detection of covid-19 antigen from nasopharyngeal swabs and typical clinical history; (3) participated in registered clinical trials and received anti-lymphoma treatment within four weeks before COVID-19 infection; (4) complete data on clinico-pathological characteristics, treatment approaches and follow-up were available.
Exclusion criteria
* Patients who could not provide detailed information about COVID-19 infection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The severity of COVID-19 | 2 months | The severity of COVID-19 infection in maligant lymphoma patients evaluated by investigators |
| Hospital admission rate of COVID-19 infection | 2 months | The percentage of malignant lymphoma patients who were admitted into hospital |
Countries
China
Outcome results
None listed